Pila Pharma AB (publ) (STO:PILA)

Market Cap	89.64M
Revenue (ttm)	957.89K
Net Income (ttm)	-11.26M
Shares Out	42.08M
EPS (ttm)	-0.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	596,685
Average Volume	286,651
Open	2.280
Previous Close	2.130
Day's Range	2.230 - 2.500
52-Week Range	1.696 - 5.560
Beta	0.41
RSI	51.86
Earnings Date	Feb 25, 2026

About Pila Pharma AB

Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 1
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: PILA

Financial Performance

In 2024, Pila Pharma AB's revenue was 789,889, a decrease of -46.01% compared to the previous year's 1.46 million. Losses were -11.24 million, 13.2% more than in 2023.